Literature DB >> 26079682

Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still's disease.

Y-J Ha1, E-J Kang2, S-W Lee3, Y-B Park3, S-K Lee3, J-S Song4, S T Choi4.   

Abstract

OBJECTIVE: To investigate whether serum leucine-rich α2-glycoprotein (LRG) levels are elevated in patients with adult-onset Still's disease (AOSD) and determine their correlation with disease activity parameters.
METHOD: We enrolled 39 patients with AOSD, 47 patients with rheumatoid arthritis (RA), and 39 controls. Forty-five serum samples from the patients with AOSD were assayed for LRG using an enzyme-linked immunosorbent assay (ELISA). Comprehensive AOSD activity was determined by a modified Pouchot score.
RESULTS: Serum LRG levels were significantly elevated in patients with AOSD (128.8±40.8 ng/mL) compared to those in patients with RA and in controls (33.9±15.2 ng/mL, p<0.001 and 22.4±6.1 ng/mL, p<0.001, respectively). Patients with active AOSD had significantly higher LRG levels than those with inactive disease (141.4±31.3 ng/mL vs. 79.8±37.1 ng/mL, p=0.002). Serum LRG levels were positively correlated with C-reactive protein (CRP; γ=0.387, p=0.015), lactate dehydrogenase (LDH; γ=0.370, p=0.026), ferritin (γ=0.687, p<0.001) levels, and the modified Pouchot score (γ=0.756, p<0.001). Serum LRG levels decreased significantly after treatment in all six patients with active AOSD who had follow-up evaluations (p=0.007). The best cut-off value for LRG to distinguish AOSD from RA was 67.9 ng/mL, with a sensitivity of 92.3% and a specificity of 97.9%.
CONCLUSIONS: Serum LRG levels were increased in patients with AOSD and correlated well with disease activity measures. LRG may be a useful biomarker for distinguishing AOSD from RA and for monitoring the disease activity of AOSD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26079682     DOI: 10.3109/03009742.2015.1016103

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  8 in total

1.  Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis.

Authors:  Masaki Shimizu; Natsumi Inoue; Mao Mizuta; Yasuo Nakagishi; Akihiro Yachie
Journal:  J Immunol Res       Date:  2019-02-04       Impact factor: 4.818

2.  Correlation of increased serum leucine-rich α2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study.

Authors:  Takaaki Ishida; Takuya Kotani; Satoshi Serada; Minoru Fujimoto; Tohru Takeuchi; Shigeki Makino; Tetsuji Naka
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.240

Review 3.  LRG1 as a novel therapeutic target in eye disease.

Authors:  Giulia De Rossi; Marlene E Da Vitoria Lobo; John Greenwood; Stephen E Moss
Journal:  Eye (Lond)       Date:  2022-01-05       Impact factor: 4.456

4.  LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells.

Authors:  Lijing Hao; Hua Xie; Bin Zhang; Dong Chen; Shufen Wang; Huiyun Zhang; Shaoheng He
Journal:  J Transl Med       Date:  2016-07-04       Impact factor: 5.531

5.  Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis.

Authors:  Minoru Fujimoto; Tomoshige Matsumoto; Satoshi Serada; Yusuke Tsujimura; Shoji Hashimoto; Yasuhiro Yasutomi; Tetsuji Naka
Journal:  Sci Rep       Date:  2020-02-25       Impact factor: 4.379

6.  Urinary Proteomics Identifying Novel Biomarkers for the Diagnosis of Adult-Onset Still's Disease.

Authors:  Yue Sun; Fan Wang; Zhuochao Zhou; Jialin Teng; Yutong Su; Huihui Chi; Zhihong Wang; Qiongyi Hu; Jinchao Jia; Tingting Liu; Honglei Liu; Xiaobing Cheng; Hui Shi; Yun Tan; Chengde Yang; Junna Ye
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561

7.  Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.

Authors:  Tetsuhiro Yoshimura; Keiichi Mitsuyama; Ryosuke Sakemi; Hidetoshi Takedatsu; Shinichiro Yoshioka; Kotaro Kuwaki; Atsushi Mori; Shuhei Fukunaga; Toshihiro Araki; Masaru Morita; Kozo Tsuruta; Hiroshi Yamasaki; Takuji Torimura
Journal:  Mediators Inflamm       Date:  2021-02-01       Impact factor: 4.711

Review 8.  LRG1: an emerging player in disease pathogenesis.

Authors:  Carlotta Camilli; Alexandra E Hoeh; Giulia De Rossi; Stephen E Moss; John Greenwood
Journal:  J Biomed Sci       Date:  2022-01-21       Impact factor: 12.771

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.